Radiation may replace drugs for some kidney cancer patients

NCT ID NCT03575611

Terminated Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether high-precision radiation (SBRT) can control kidney cancer that has spread to a few spots in the body. The goal is to see if radiation alone can delay or replace the need for systemic drug therapy. The study involves 123 participants and includes biopsies and imaging before and after treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: stereotactic body radiation therapy (SBRT)
What this could lead to: If successful, this approach could offer a way to control metastatic kidney cancer with radiation alone, potentially delaying or avoiding the need for systemic drug therapy.
What could go wrong: This is a small, early-phase trial that is currently suspended. It is unclear if radiation alone can effectively control the disease long-term, and not all patients may be suitable candidates.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC RENAL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

renal cell adenocarcinoma renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC RENAL CELL CARCINOMA STAGE IV RENAL CELL CANCER AJCC V8

Contacts and locations

Locations

M D Anderson Cancer Center

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.